Introduction to the Pancreatic Cancer PC Animal Model

Pancreatic cancer (PC) is a common malignancy of the digestive system, characterized by an insidious onset, high malignancy, poor response to chemotherapy, and rapid disease progression. Coupled with the pancreas’s unique anatomical location and low tumor resection rates, it is highly prone to recurrence and has a poor prognosis. Establishing animal models of pancreatic cancer facilitates research into its pathogenesis, evaluation of drug efficacy, and the development of novel therapeutic strategies.

Service Advantages of Aniphe BioLab’s PC Animal Model Platform

Our platform boasts a well-established pancreatic cancer (PC) animal model system that accurately recapitulates tumor progression and the ensuing hepatic injury and liver failure, providing comprehensive support for related research and drug‑efficacy evaluation.

	High degree of symptom fidelity The typical pancreatic cancer–related lesions were consistently reproduced, along with secondary signs of liver failure, including abnormal liver enzymes, jaundice, ascites, and coagulation and metabolic disturbances.
	The model has good stability. The modeling success rate is high, individual variability is minimal, experimental results are highly reproducible, and the data are reliable.
	Standardized Control and Management Throughout the entire process, animals are raised under SPF-grade conditions, with standardized procedures and continuous health monitoring, ensuring compliance and full traceability.
	Comprehensive testing system It can perform multi-dimensional testing and analysis, including pathology, biochemistry, imaging, and molecular markers.
	One-stop service We offer end-to-end services spanning model generation, animal husbandry, sample collection, and assay analysis, ensuring efficient project execution.

Modeling cycle	About 2 weeks
Laboratory animals	Balb/c-nude
Positive drug	Gemcitabine, nab‑paclitaxel, and other commonly used agents are employed as positive control anticancer drugs, in combination with hepatoprotective and enzyme‑lowering medications for comparative evaluation.
Application areas	It is widely employed in research on the mechanisms of pancreatic cancer initiation and progression, screening of anti‑tumor drugs, investigation of the tumor microenvironment and stroma, studies of tumor invasion and metastasis, evaluation of immunotherapy, as well as the development of precision medicine and combination‑therapy strategies, thereby providing a crucial experimental platform for basic pancreatic cancer research and the discovery of innovative therapeutics.

Construction of PC animal models

The pancreatic heterotopic orthotopic transplantation model (using BON-1 cells) involves implanting human pancreatic neuroendocrine tumor cells—BON-1—under the pancreatic capsule of experimental animals to establish an orthotopic pancreatic cancer model. Following tumor establishment, as the tumor progresses with local invasion and distant metastasis, the animals develop hallmark clinical signs such as hepatocellular necrosis, elevated liver enzymes, jaundice, and ascites, accompanied by impaired hepatic metabolism and coagulation function. This closely recapitulates the clinicopathological features of acute liver failure secondary to pancreatic cancer.

Anatomy of Pancreatic Tissue

As indicated by the scale bar, the tumor measures approximately 5–6 mm in diameter and exhibits a well‑defined, rounded morphology, suggesting successful engraftment and sustained proliferation within the pancreas—features consistent with the typical pathological hallmarks of an orthotopic pancreatic tumor model.